Critical Review: Chromadex (CDXC) vs. Its Peers

Chromadex (NASDAQ: CDXC) is one of 184 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Chromadex to similar companies based on the strength of its dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent recommendations for Chromadex and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 3 0 3.00
Chromadex Competitors 543 2453 6662 127 2.65

Chromadex currently has a consensus target price of $7.00, suggesting a potential upside of 16.28%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.36%. Given Chromadex’s peers higher probable upside, analysts clearly believe Chromadex has less favorable growth aspects than its peers.

Insider and Institutional Ownership

6.8% of Chromadex shares are owned by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 11.6% of Chromadex shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares Chromadex and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -21.89% -47.30% -32.25%
Chromadex Competitors -4,719.05% -483.08% -43.32%

Earnings & Valuation

This table compares Chromadex and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Chromadex $26.81 million -$2.92 million -26.17
Chromadex Competitors $217.29 million -$39.39 million -77.66

Chromadex’s peers have higher revenue, but lower earnings than Chromadex. Chromadex is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Chromadex has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Chromadex’s peers have a beta of 1.54, suggesting that their average stock price is 54% more volatile than the S&P 500.


Chromadex beats its peers on 7 of the 13 factors compared.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

What are top analysts saying about Chromadex? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chromadex and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit